acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Company profile
Ticker
ACAD
Exchange
Website
CEO
Stephen Davis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ACADIA Pharmaceuticals A/S • ACADIA Pharmaceuticals GmbH • ACADIA Pharma Limited • CerSci Therapeutics Incorporated • Amorsa Therapeutics Inc. • Acadia Pharmaceuticals Holdings Inc. • Levo Therapeutics, Inc. ...
IRS number
61376651
ACAD stock data
Latest filings (excl ownership)
8-K
Other Events
11 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
27 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Other Events
21 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
2 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
2 Aug 23
8-K
Entry into a Material Definitive Agreement
18 Jul 23
Transcripts
ACAD
Earnings call transcript
2023 Q4
27 Feb 24
ACAD
Earnings call transcript
2023 Q3
2 Nov 23
ACAD
Earnings call transcript
2023 Q2
2 Aug 23
ACAD
Earnings call transcript
2023 Q1
8 May 23
ACAD
Earnings call transcript
2022 Q4
27 Feb 23
ACAD
Earnings call transcript
2022 Q3
3 Nov 22
ACAD
Earnings call transcript
2022 Q2
9 Aug 22
ACAD
Earnings call transcript
2022 Q1
5 May 22
ACAD
Earnings call transcript
2021 Q4
1 Mar 22
ACAD
Earnings call transcript
2021 Q3
9 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.96 mm | 103.96 mm | 103.96 mm | 103.96 mm | 103.96 mm | 103.96 mm |
Cash burn (monthly) | 4.03 mm | 4.72 mm | 19.26 mm | 12.59 mm | 19.65 mm | 7.71 mm |
Cash used (since last report) | 27.64 mm | 32.36 mm | 132.00 mm | 86.29 mm | 134.70 mm | 52.86 mm |
Cash remaining | 76.32 mm | 71.61 mm | -28.04 mm | 17.67 mm | -30.73 mm | 51.11 mm |
Runway (months of cash) | 18.9 | 15.2 | -1.5 | 1.4 | -1.6 | 6.6 |
Institutional ownership, Q3 2023
93.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 244 |
Opened positions | 40 |
Closed positions | 28 |
Increased positions | 91 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 3.20 tn |
Total shares | 154.43 mm |
Total puts | 1.40 mm |
Total calls | 1.02 mm |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 42.86 mm | $893.30 bn |
Vanguard | 13.62 mm | $283.77 bn |
RTW Investments | 11.58 mm | $241.26 bn |
BLK Blackrock | 10.03 mm | $209.00 bn |
EcoR1 Capital | 5.99 mm | $124.86 bn |
FMR | 5.30 mm | $110.49 bn |
T. Rowe Price | 5.23 mm | $109.05 bn |
STT State Street | 5.21 mm | $108.65 bn |
D. E. Shaw & Co. | 4.79 mm | $99.80 bn |
Fred Alger Management | 3.11 mm | $64.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Davis Stephen | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 17,716 | 316.58 k | 144,267 |
8 Apr 24 | Davis Stephen | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 8,858 | 158.29 k | 161,983 |
8 Apr 24 | Brendan Teehan | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 2,568 | 45.89 k | 38,796 |
8 Apr 24 | James Kihara | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 762 | 13.62 k | 13,100 |
8 Apr 24 | James Kihara | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 1,028 | 18.37 k | 13,862 |
8 Apr 24 | Mark C. Schneyer | Common Stock | Sell | Dispose S | No | Yes | 17.87 | 2,716 | 48.53 k | 28,742 |
7 Apr 24 | James Kihara | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,489 | 0.00 | 14,890 |
7 Apr 24 | James Kihara | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,489 | 0.00 | 0 |
5 Apr 24 | Davis Stephen | Common Stock | Option exercise | Acquire M | No | No | 0 | 34,666 | 0.00 | 170,841 |
5 Apr 24 | Davis Stephen | Common Stock | Option exercise | Acquire M | No | No | 0 | 17,333 | 0.00 | 136,175 |
News
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
17 Apr 24
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
10 Apr 24
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
10 Apr 24
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
9 Apr 24
Expert Ratings For ACADIA Pharmaceuticals
25 Mar 24
Press releases
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
24 Apr 24
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
22 Apr 24
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Apr 24
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
17 Apr 24
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
2 Apr 24